A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid‐derived suppressor cells for Agaricus bisporus–induced prostate‐specific antigen responses

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|17|2942-2950

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.17, 2015-09, pp. : 2942-2950

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prostate Cancer Screening with Prostate-Specific Antigen in Hemodialysis Patients

By  

Urologia Internationalis, Vol. 78, Iss. 4, 2007-05 ,pp. : 334-337

Karger

Access to resources Recommend Favorite

A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination

By  

THE PROSTATE, Vol. 75, Iss. 14, 2015-10 ,pp. : 1518-1525

John Wiley & Sons Inc

Access to resources Recommend Favorite

The relationship between prostate‐specific antigen and TNM classification or Gleason score in prostate cancer patients with low prostate‐specific antigen levels

By  

THE PROSTATE, Vol. 75, Iss. 10, 2015-07 ,pp. : 1034-1042

John Wiley & Sons Inc

Access to resources Recommend Favorite

Myeloid-Derived Suppressor Cells: Paradoxical Roles in Infection and Immunity

By  

Journal of Innate Immunity, Vol. 7, Iss. 2, 2014-11 ,pp. : 116-126

Karger

Access to resources Recommend Favorite

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate‐specific antigen and biopsy outcome

By  

CANCER, Vol. 119, Iss. 16, 2013-08 ,pp. : 3007-3011

John Wiley & Sons Inc

Access to resources Recommend Favorite